The top 100 biotech VCs: Who's staying at the table and what do they want now?
As we all know only too well, the old playbook on biotech investing got thrown out the window with the end of the IPO boom at the beginning of 2022. We recently tracked VCs’ performance last year and listed the top 100 players in the field. And then I gathered a group of top VCs to talk about how it’s all working in 2023. Here’s our conversation.
This transcript has been edited for brevity and clarity.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.